

## Product Specification Sheet

**Product Name:** FG-4592

**Catalog Number:** C3445

**Technical information:**

Chemical Formula:  $C_{19}H_{16}N_2O_5$

CAS #: 808118-40-3

Molecular Weight: 352.34

Purity: > 98%


Appearance: Yellow solid

Solubility: Soluble in DMSO up to 100 mM

Chemical Name: 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid

Storage: Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.



- Handling:**
- To make 10 mM stock solution, add 0.284mL of DMSO for each mg of FG-4592
  - For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

**Biological Activity:** FG-4592 is an orally-available isoquinoline-based inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase for the treatment of anemia and patients with chronic kidney disease. [1] Phase 2 studies indicate that oral administration of FG-4592 three times a week increased mean hemoglobin levels in the first eight weeks, regardless of supplementation with IV or oral iron, or no iron supplementation. FG-4592 is novel in that it allows integration of red blood cell production and efficient iron incorporation simultaneously. [1]

Data from Phase 2 trials comparing with epoetin alpha indicate that treatment with FG-4592 alone results in a sustained reduction of total plasma cholesterol levels by an average of 20%, while no reduction was seen with epoetin alpha. [2, 3]

In December, 2012, Fibrogen and Astellas Pharma announced the initiation of a Phase 3 clinical development program for the treatment of anemia associated with chronic kidney disease in patients not on dialysis and on dialysis. [4]

- Reference:**
1. "Correction of anemia without IV iron supplementation in incident dialysis patients" Fibrogen press release,
  2. "FG-4592 and epoetin alpha in Phase II anemia study", Datamonitor Research Store, Nov. 11, 2012.
  3. "Hemoglobin correction and maintenance in end-stage renal patients" Fibrogen press release, Nov. 5, 2012
  4. Fibrogen press release, Dec. 11, 2012 (Phase 3 announcement)

To reorder: <http://www.cellagentech.com/FG-4592/>

For Technical Support: [technical@cellagentech.com](mailto:technical@cellagentech.com)

*Chemicals are sold for research use only, not for clinical or diagnostic use.*